Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients ...

Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2 ...

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.

Argenx (ARGX) stock rises as the FDA approves Vyvgart Hytrulo developed with Halozyme (HALO) for self-injection, the drug's ...

The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive and adults with chronic inflammatory ...

Piper Sandler analysts highlighted their top picks for biotechnology for investors amid the rollercoaster seen in the equity ...

FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options.